Cognetivity Neurosciences (CSE: CGN) has been selected as one of just seven members of the Texas Medical Center Innovation Accelerator program, also known as TMCx. The program seeks to find what is referred to as “breakthrough healthcare technologies,” with an eye to enabling commercialization of the tech. The company was the only selected participant to not be US-based for the program.
Initial selection phases of the program are said to be based on addressable market size, technological novelty and strength, and the overall fit for the program. Out of 170 applicants from 20 separate countries, Cognetivity is the only operator selected that is not US-based, a notable achievement for the Vancouver based firm.
Now that it has been selected as part of the medical accelerator program, the company will gain access to medical networks across the US that are heavily focused on innovation to tackle today’s healthcare needs, thereby increasing the firms resources and network supports to push US market penetration. The prior phase of the program enabled the company to explore commercial opportunities for its product, as well as potential partnerships with institutions within the network. Feedback from this prior stage was instrumental in propelling the company into the final phase of the program.
Cognetivity is currently focused on technological innovation, with its flagship product focused on that of Alzheimer’s. The company has developed a testing platform that can be used in medical, commercial, and consumer environments that implements artificial intelligence and machine learning to detect the very earliest signs of impairment that could be a sign of dementia. The tech works by repeatedly testing the performance of large areas of the brain which in turn supports a diagnosis of dementia where appropriate.
“Having such immediate access to an engaged network of potential US commercial partners enables companies like ours, with unique technology able to help address a major health crisis, to break through the noise and make meaningful progress quickly. We [..] already have some very exciting partnership opportunities evolving rapidly with some of the TMC members. We look forward to strengthening those relationships and developing further opportunities in the months ahead that build on our early traction in clinical use in the UK NHS.”
Sina Habibi, Cogentivity founder and CEO
Cognetivity Neurosciences last traded at $0.47 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
